title: Correlation between loss of Bcl-XL expression and improved prognosis in advanced esophageal cancer treated by preoperative chemoradiotherapy.
abstract: We investigated the clinical significance of the apoptosis- related molecule expression of tumor cells in patients with advanced esophageal cancer treated with preoperative chemoradiotherapy (CRT). Preoperative CRT reduced Bcl-X(L) expression in a significant proportion of the group responding to CRT but not in the group resisting CRT, although Bcl-2 expression was reduced in both groups. The mean survival time of the patients with cancers that lost Bcl-X(L) following CRT was significantly longer compared to those with cancers expressing Bcl-X(L). These results suggested that CRT reduced Bcl-X(L) expression, and this decrease closely correlated with the prolonged survival of advanced esophageal cancer patients treated with preoperative CRT.
authors.affiliation: Department of Gastroenterological Surgery, Juntendo University School of Medicine, Tokyo, Japan. okumasa@med.juntendo.ac.jp
authors.forename: M
authors.initials: M
authors.lastname: Okumura
authors.forename: Y
authors.initials: Y
authors.lastname: Kajiyama
authors.forename: K
authors.initials: K
authors.lastname: Takeda
authors.forename: K
authors.initials: K
authors.lastname: Okumura
authors.forename: M
authors.initials: M
authors.lastname: Tsurumaru
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D017209:Apoptosis / Q000235:genetics; D001483:Base Sequence; D053148:Caspase 3 / Q000235:genetics; D053181:Caspase 8 / Q000235:genetics; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D017931:DNA Primers / Q000235:genetics; D000077143:Docetaxel; D004938:Esophageal Neoplasms / Q000235:genetics* / Q000473:pathology / Q000628:therapy*; D053200:Fas-Associated Death Domain Protein / Q000235:genetics; D005260:Female; D015870:Gene Expression; D019254:Genes, bcl-2; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D012334:RNA, Neoplasm / Q000235:genetics / Q000378:metabolism; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use; D020133:Reverse Transcriptase Polymerase Chain Reaction; D043823:Taxoids / Q000627:therapeutic use; D051020:bcl-X Protein / Q000235:genetics*
chemical_list: D000970:Antineoplastic Agents; C494811:BCL2L1 protein, human; D017931:DNA Primers; C505533:FADD protein, human; D053200:Fas-Associated Death Domain Protein; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D011838:Radiation-Sensitizing Agents; D043823:Taxoids; D051020:bcl-X Protein; D000077143:Docetaxel; C505407:CASP3 protein, human; C505530:CASP8 protein, human; D053148:Caspase 3; D053181:Caspase 8